About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Variance of HRD From Paired Ovarian Cancer | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNNCT05069818

Variance of HRD From Paired Ovarian Cancer

Homologous recombination deficiency (HRD) is an important biomarker of poly (ADP-ribose) polymerase inhibitor (PARPi) in patients with high-grade serous ovarian cancer (HGSOC). The stability of HRD in...

Lead sponsor: Xiaoxiang Chen•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Contacts

Jing Ni, MD

CONTACT

+86 13327833586 nijingwulin@126.com

Xiaoxiang Chen, MD,PhD

CONTACT

Sponsors

Lead Sponsor

Xiaoxiang Chen

This study intends to perform HRD testing of ovarian cancer in the recurrent HGSOC and its primary pair, furtherly correlate HRD status and clinical characteristics in the recurited population.

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

Inclusion Criteria

•1. Subjects join the study voluntarily and sign informed consent;
•2. Female subjects are older than 18 years;
•3. ECOG(Eastern Cooperative Oncology Group) physical status score is 0-2;
•4. Life expectancy≥3 months;
•5. Histologically confirmed FIGO(International Federation of Gynecology and Obstetrics ) III/IV ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; Participants must have high-grade serous histology

Exclusion Criteria

•1. Personnel involved in the formulation or implementation of the research plan;
•2. The subjects had other malignant diseases in past 2 years, except skin squamous cell carcinoma, basal-like carcinoma, breast intraductal carcinoma in situ, or cervical carcinoma in situ;

Related studies

Familial Investigations of Childhood Cancer Predisposition

NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more

RECRUITINGPhase 1

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

NCT06257264 · Breast Cancer, Small Cell Lung Cancer, and more

RECRUITINGPhase 1

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

NCT06964009 · Ovarian Cancer, Ovarian Carcinoma, and more

Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

NCT00539162 · Ovarian Cancer

REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

NCT06710548 · Ovarian Cancer, Advanced Ovarian Carcinoma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 6, 2021Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment50

Start dateOct 2021

Last updatedOct 6, 2021

Condition

Ovarian Cancer HRD Platinum-sensitive Ovarian Cancer

Locations shown

Xiaoxiang Chen

Nanjing, Jiangsu

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 6, 2021Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions